• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600216.SS
Share

Zhejiang Medicine Co., Ltd. Stocks

CN¥ 11.99Last Updated 26.10.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.72B

CN¥ 11.99
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Medicine Co., Ltd. is a Chinese enterprise specializing in the manufacturing and distribution of both nutritional supplements and pharmaceutical goods. Its life nutrition portfolio encompasses a wide array of offerings, such as synthetic and natural vitamin E, vitamin A, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, and lycopene, alongside various other vitamin compounds. Beyond nutrition, the company is a significant supplier in the pharmaceutical sector. This includes the production of active pharmaceutical ingredients and raw materials like specialized antibiotics for drug-resistant strains, anti-malarial compounds, and quinolone derivatives. Furthermore, it develops and markets finished pharmaceutical products, notably sugar-based medications and hormonal preparations. Established in 1997, Zhejiang Medicine Co., Ltd. maintains its headquarters in Shaoxing, China.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 600216.SS is 17.4 and suggests 46.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 01:51

Anthropic Disclosed Its Reliance on Google, Amazon, and Microsoft Ahead of Its IPO. What Is the Risk?

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026